Masimo (NASDAQ:MASI) had its target price hoisted by Raymond James from $235.00 to $250.00 in a research note issued to investors on Wednesday, BenzingaRatingsTable reports. Raymond James currently has an outperform rating on the medical equipment provider’s stock.
A number of other equities research analysts also recently commented on MASI. Stifel Nicolaus lifted their price target on shares of Masimo from $200.00 to $245.00 and gave the stock a buy rating in a report on Wednesday, April 29th. BidaskClub upgraded shares of Masimo from a hold rating to a buy rating in a report on Wednesday, July 8th. UBS Group lifted their price target on shares of Masimo from $207.00 to $245.00 and gave the stock a buy rating in a report on Thursday, April 30th. ValuEngine downgraded shares of Masimo from a buy rating to a hold rating in a report on Friday, May 1st. Finally, BTIG Research reiterated a hold rating on shares of Masimo in a report on Thursday, July 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $216.14.
NASDAQ:MASI opened at $220.12 on Wednesday. The firm has a 50-day moving average price of $228.29 and a two-hundred day moving average price of $202.59. Masimo has a twelve month low of $139.36 and a twelve month high of $258.00. The company has a market capitalization of $12.10 billion, a P/E ratio of 57.03, a price-to-earnings-growth ratio of 4.11 and a beta of 0.92.
In other Masimo news, Director Adam Mikkelson sold 1,498 shares of Masimo stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $216.01, for a total transaction of $323,582.98. Following the transaction, the director now directly owns 2,802 shares of the company’s stock, valued at $605,260.02. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Jon Coleman sold 1,250 shares of Masimo stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $235.00, for a total transaction of $293,750.00. Following the transaction, the insider now directly owns 13,715 shares in the company, valued at $3,223,025. The disclosure for this sale can be found here. Insiders sold 3,335 shares of company stock worth $749,625 over the last three months. Corporate insiders own 11.50% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. C M Bidwell & Associates Ltd. acquired a new position in Masimo during the first quarter valued at approximately $25,000. Parallel Advisors LLC lifted its position in shares of Masimo by 272.1% during the second quarter. Parallel Advisors LLC now owns 160 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 117 shares in the last quarter. Credit Agricole S A acquired a new position in shares of Masimo during the first quarter worth $29,000. Altshuler Shaham Ltd lifted its position in shares of Masimo by 91.0% during the first quarter. Altshuler Shaham Ltd now owns 170 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 81 shares in the last quarter. Finally, GQ Asset Management LLC acquired a new position in shares of Masimo during the first quarter worth $32,000. 84.39% of the stock is currently owned by hedge funds and other institutional investors.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Article: Swap
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.